ADT and risk for diagnosis with dementia? “Not in the UK”, they say!

Just a few weeks ago we reported data from a study in California suggesting an association between treatment with androgen deprivation therapy (ADT) for prostate cancer and subsequent risk for diagnosis with dementia or Alzheimer’s disease.

Almost inevitably, it would seem, there now comes a newer paper suggesting no such association at all.

Khosrow-Khavar et al. report the following:
  • The average (mean) patient follow-up was 4.3 ± 3.6 years.
  • During that follow-up period
    • 799 /30,903 men with prostate cancer (2.6 percent) were diagnosed with dementia.
    • The age-adjusted incidence of dementia among these prostate cancer patients was 6.0 cases per 1,000 person-years.
  • Comparing the risk for dementia among ADT users as compared to non-ADT users,
    • The age-adjusted incidence of dementia among non-users of ADT was 4.4 cases per 1,000 person-years.
    • The age-adjusted incidence of dementia among users of ADT was 7.4 cases per 1,000 person-years
    • The adjusted hazard ratio for risk of dementia among the users was 1.02.
    • This difference in age-adh=justed risk was not statistically significant.
  • Neither cumulative duration of use of ADT nor the use of any one specific type of ADT was associated with increased risk for dementia.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: